Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Comparing normal and anaemic hands © Shutterstock

Many patients with inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis also develop anaemia, which may impair their ability to exercise and perform normal activities. The cause of this anaemia is complex but is partly attributable to the effects of inflammatory molecules (cytokines) on the bone marrow, which produces new blood cells.

In work recently published in the Journal of Experimental Medicine, a team of researchers from the Kennedy Institute of Rheumatology led by Dr Thibault Griseri, shows that the cytokine interleukin-33 (IL-33) suppresses the production of new red blood cells in an experimental model of inflammatory arthritis and in human cells. This novel effect is caused by a direct effect of IL-33 to inhibit differentiation of red blood cell progenitors into mature cells.

"We are delighted to be able to share our work investigating a new pathway causing anaemia during inflammation. Anaemia is a common problem in patients with inflammatory diseases and we believe this work opens up a new area for development of possible therapies", said James Swann, DPhil student and first author of the paper.

This work identifies a new potential target for treatment of anaemia occurring as a comorbidity in patients with chronic inflammatory diseases.

The study was funded by Versus Arthritis, the Kennedy Trust for Rheumatology Research and the Wellcome Trust, and was a collaboration between the Griseri Lab and the Sansom Group at the Kennedy Institute.

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.